Onconetix ONCO

NASDAQ ONCO

$0.41 -0.02 (-5.55%)

At close: Oct 20, 2026 · 4:00 PM EDT

Onconetix (ONCO) stock price is $0.41, down 5.55% on the day, as of Oct 20, 2026. It has a market cap of $889.71K, and is classified in the Diagnostic Equipment industry (Healthcare sector).

Key Stats

Market Cap889,706.85

P/E-0.09

P/S1.38

Div. Yield0.00

Total Debt (Qtr)150,394.00

Revenue Growth (1y) (Qtr)-83.92

Add ratio to table…

About

Onconetix, Inc. is a commercial stage biotechnology company engaged in the research, development, and commercialization of diagnostic and therapeutic products for men's health and oncology. The company's primary asset is Proclarix, an in vitro diagnostic test for prostate cancer that measures thrombospondin 1 and cathepsin D biomarkers and generates a risk score to aid biopsy decisions. Proclarix received CE marking under the European In Vitro Diagnostic Directive on January 31, 2019 and subsequently obtained CE marking under the In Vitro Diagnostic Regulation on October 7, 2022, allowing sale in the European Union, the United Kingdom and Switzerland. Onconetix previously acquired the therapeutic product ENTADFI, an FDA approved once daily pill combining finasteride and tadalafil for benign prostatic hyperplasia, but abandoned its commercialization due to cash constraints and no longer holds inventory of that product. The company is headquartered in Cincinnati, Ohio and operates through its wholly owned subsidiary Proteomedix, which holds the Proclarix intellectual property and related know-how. Proclarix is designed for use in men with total PSA levels between 2.0 and 10.0 ng/mL, a normal digital rectal exam and a prostate volume of at least 35 mL, targeting the population where biopsy decisions are most uncertain.

Onconetix generates revenue mainly from the sale of Proclarix tests to diagnostic laboratories and healthcare providers in Europe, where patients typically pay out of pocket because the test is not currently reimbursed by public or private payers. The company also expects future revenue from the United States under an exclusive license agreement with LabCorp, which will develop and commercialize Proclarix as a lab developed test for the U. S. market. In 2025, Proclarix sales totaled $23,091, reflecting early stage market adoption in selected European laboratories. As of December 31, 2025, Onconetix reported cash of approximately $5.2 million, a working capital deficit of about $3.1 million and an accumulated deficit of roughly $131.2 million. During the year ended December 31, 2025, the company used approximately $9.7 million in cash for operating activities. To support near term operations, Onconetix completed Series D and Series E private placements in September and October 2025, raising aggregate net proceeds of approximately $15.5 million. The company continues to rely on external financing to fund product development, commercialization efforts and general corporate expenses until it can achieve sustainable revenue streams. The company's cash runway has been supplemented by the proceeds from the PIPE financings, which are intended to support operations for the next twelve months while it pursues regulatory clearance and commercial scale up of Proclarix in the United States.

Onconetix positions Proclarix as a blood based immunoassay test that helps clinicians determine whether a prostate biopsy is warranted for men with elevated prostate specific antigen levels in the diagnostic grey zone. The assay uses two enzyme linked immunosorbent assays to quantify thrombospondin 1 and cathepsin D, which are combined with age and total and free PSA values in a proprietary algorithm to produce a risk score. Clinical validation studies have demonstrated that Proclarix can reduce unnecessary biopsies by approximately 43% compared with standard PSA based approaches, while maintaining a sensitivity above 90% and a negative predictive value exceeding 90% for clinically significant prostate cancer. In magnetic resonance imaging guided biopsy settings, the test's sensitivity rises to 97% and the negative predictive value reaches 96%. Competitors in the prostate cancer risk assessment market include the percent free PSA test, the 4Kscore, the phi score and the Stockholm3 test, which generally offer more modest improvements in specificity and predictive value. The worldwide in vitro diagnostic market was valued at approximately $109 billion in 2025, with prostate cancer representing a significant segment due to high incidence and ongoing screening practices. Onconetix believes its competitive advantages derive from the test's blood based nature, which eliminates the need for invasive procedures such as prostate massage, its high reproducibility and stability for shipment at ambient temperature, its compatibility with routine laboratory equipment using enzyme linked immunosorbent assay technology, its ease of automation and fast turnaround time, its objective result generation that is independent of operator variability and its foundation in genetics guided biomarker discovery linked to the PI3K/PTEN pathway. Additionally, Proclarix is classified as a class C in vitro diagnostic device under the European In Vitro Diagnostic Regulation and is manufactured under an ISO 13485:2016 certified quality management system, reinforcing its regulatory compliance and analytical reliability.

The company sells Proclarix to diagnostic laboratories, hospitals and clinics across Europe, with established pilot programs in Switzerland, Germany, Italy and the United Kingdom where the test is offered to urologists and general practitioners as an aid in prostate cancer triage. In these markets, patients typically bear the cost of the test directly because reimbursement pathways are not yet in place. In the United States, LabCorp holds an exclusive license to develop and commercialize Proclarix, positioning it as the primary partner for future U. S. market access and enabling the test to be offered through LabCorp's extensive network of laboratories and patient service centers. Onconetix has also entered into licensing discussions with Immunovia AB relating to pancreatic cancer biomarker applications, although those arrangements are separate from its core prostate cancer diagnostic business. The ultimate end users of Proclarix are patients undergoing prostate cancer evaluation, who benefit from a non invasive blood test that can help avoid unnecessary biopsies and associated complications. By providing an objective risk score, Proclarix aims to reduce patient anxiety, lower healthcare system costs associated with unnecessary biopsies and improve overall diagnostic pathway efficiency.

Investment Thesis

▲ Bull case

Onconetix Inc. stands to gain transformational value from the acquisition of RealLLC by pivoting from a niche oncology diagnostics business into the rapidly expanding AI-powered humanoid robotics sector, a move that leverages RealLLC’s patented technologies in embodied AI, lifelike expressions, and autonomous social interaction—capabilities that are increasingly critical in commercial applications such as healthcare, hospitality, and customer service. This strategic shift positions ONCO to tap into a global humanoid robotics market projected to exceed $38 billion by 2030, according to industry forecasts, with early-mover advantage in enterprise-facing roles where labor shortages and rising operational costs are driving adoption. The transaction effectively rebrands ONCO as a U.S.-based innovator in physical AI, a narrative far more compelling to growth-oriented investors than its legacy oncology focus, which has struggled with limited commercialization and reimbursement challenges. By absorbing RealLLC’s engineering and AI software teams, ONCO gains immediate R&D capacity without the years-long build-out typically required to develop such complex systems, accelerating product deployment timelines and reducing capital intensity. Furthermore, the all-stock structure preserves cash resources while aligning incentives, as Realbotix retains 75–90% ownership and board control, ensuring continued operational excellence and technological leadership post-transaction. The NASDAQ listing of the combined entity will enhance visibility, attract institutional capital, and provide a liquidity pathway for shareholders—factors historically undervalued in ONCO’s current biotech valuation, which remains depressed due to slow Proclarix® adoption and limited U.S. market penetration. This transformation could rerate the stock toward comparables in the AI and robotics space, where premium multiples are justified by scalable software-hardware integration and recurring service models, rather than the binary outcomes typical of early-stage biotech.

Onconetix Inc. stands to gain transformational value from the acquisition of RealLLC by pivoting from a niche oncology diagnostics business into the rapidly expanding AI-powered humanoid robotics sector, a move that leverages RealLLC’s patented technologies in embodied AI, lifelike expressions, and autonomous social interaction—capabilities that are increasingly critical in commercial applications such as healthcare, hospitality, and customer service. This strategic shift positions ONCO to tap into a global humanoid robotics market projected to exceed $38 billion by 2030, according to industry forecasts, with early-mover advantage in enterprise-facing roles where labor shortages and rising operational costs are driving adoption. The transaction effectively rebrands ONCO as a U.S.-based innovator in physical AI, a narrative far more compelling to growth-oriented investors than its legacy oncology focus, which has struggled with limited commercialization and reimbursement challenges. By absorbing RealLLC’s engineering and AI software teams, ONCO gains immediate R&D capacity without the years-long build-out typically required to develop such complex systems, accelerating product deployment timelines and reducing capital intensity. Furthermore, the all-stock structure preserves cash resources while aligning incentives, as Realbotix retains 75–90% ownership and board control, ensuring continued operational excellence and technological leadership post-transaction. The NASDAQ listing of the combined entity will enhance visibility, attract institutional capital, and provide a liquidity pathway for shareholders—factors historically undervalued in ONCO’s current biotech valuation, which remains depressed due to slow Proclarix® adoption and limited U.S. market penetration. This transformation could rerate the stock toward comparables in the AI and robotics space, where premium multiples are justified by scalable software-hardware integration and recurring service models, rather than the binary outcomes typical of early-stage biotech.

▼ Bear case

Onconetix Inc. faces substantial execution and integration risks in acquiring RealLLC that the market may be overlooking, particularly given ONCO’s historical lack of experience in hardware manufacturing, robotics engineering, or commercializing physical AI systems—core competencies that RealLLC has developed over years but which remain unproven at scale in regulated environments like healthcare and hospitality. The transaction assumes seamless transfer of intellectual property, engineering talent, and operational continuity, yet no detail is provided on employee retention plans, cultural integration between ONCO’s biotech team and RealLLC’s robotics division, or potential disruption to ongoing product development cycles, all of which could erode the very value the deal seeks to capture. Furthermore, RealLLC’s estimated book value of $1.8 million—representing just 18% of Realbotix’s balance sheet—suggests limited tangible assets, raising concerns about whether the assigned equity stake (75–90% of ONCO) is justified without clear near-term revenue visibility, customer contracts, or a path to profitability in a capital-intensive industry where gross margins are often pressured by component costs and customization demands. The oncology legacy business, including Proclarix®, continues to face headwinds: despite EU approval under IVDR, its U.S. launch as a lab-developed test via Labcorp remains uncertain, with no timeline provided and historical delays in similar LDTs due to CLIA complexities and payer skepticism, meaning ONCO may be burdened with a declining cash burn from a legacy segment while investing heavily in an unprofitable robotics venture. Additionally, the sliding scale ownership structure tied to ONCO’s net cash at closing introduces valuation ambiguity—if ONCO’s cash position is weaker than expected due to ongoing biotech operations or audit delays (noted in the upcoming February 13 call), Realbotix could receive a higher equity stake, further diluting remaining ONCO shareholders without proportional value infusion. Finally, the reliance on forward-looking statements about market growth in humanoid robotics ignores near-term barriers such as regulatory uncertainty around AI autonomy in public spaces, liability concerns in healthcare settings, and consumer skepticism toward lifelike machines—factors that could delay adoption far beyond optimistic forecasts, leaving ONCO overpaying for a business whose commercial trajectory remains highly speculative.

Onconetix Inc. faces substantial execution and integration risks in acquiring RealLLC that the market may be overlooking, particularly given ONCO’s historical lack of experience in hardware manufacturing, robotics engineering, or commercializing physical AI systems—core competencies that RealLLC has developed over years but which remain unproven at scale in regulated environments like healthcare and hospitality. The transaction assumes seamless transfer of intellectual property, engineering talent, and operational continuity, yet no detail is provided on employee retention plans, cultural integration between ONCO’s biotech team and RealLLC’s robotics division, or potential disruption to ongoing product development cycles, all of which could erode the very value the deal seeks to capture. Furthermore, RealLLC’s estimated book value of $1.8 million—representing just 18% of Realbotix’s balance sheet—suggests limited tangible assets, raising concerns about whether the assigned equity stake (75–90% of ONCO) is justified without clear near-term revenue visibility, customer contracts, or a path to profitability in a capital-intensive industry where gross margins are often pressured by component costs and customization demands. The oncology legacy business, including Proclarix®, continues to face headwinds: despite EU approval under IVDR, its U.S. launch as a lab-developed test via Labcorp remains uncertain, with no timeline provided and historical delays in similar LDTs due to CLIA complexities and payer skepticism, meaning ONCO may be burdened with a declining cash burn from a legacy segment while investing heavily in an unprofitable robotics venture. Additionally, the sliding scale ownership structure tied to ONCO’s net cash at closing introduces valuation ambiguity—if ONCO’s cash position is weaker than expected due to ongoing biotech operations or audit delays (noted in the upcoming February 13 call), Realbotix could receive a higher equity stake, further diluting remaining ONCO shareholders without proportional value infusion. Finally, the reliance on forward-looking statements about market growth in humanoid robotics ignores near-term barriers such as regulatory uncertainty around AI autonomy in public spaces, liability concerns in healthcare settings, and consumer skepticism toward lifelike machines—factors that could delay adoption far beyond optimistic forecasts, leaving ONCO overpaying for a business whose commercial trajectory remains highly speculative.

Geographical Breakdown of Revenue (2025)

History

Product Or Service Breakdown of Revenue (2025)

History

Peer percentiles

How Onconetix ranks

Ranked against the 248 companies in Medical Devices and Diagnostics58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.12xMedian 28.9x 6^th
P/FCFNegative free cash flow −0.12xMedian 26.0x 4^th
P/Operating cash flowNegative operating cash flow −0.12xMedian 20.1x 4^th
P/S 1.91xMedian 3.07x 66^th
P/B 0.09xMedian 2.40x 97^th
P/Tangible book 0.09xMedian 3.05x 98^th
EV/EBITDANet cash exceeds market value 0.28xMedian 18.0x Not meaningful —
EV/EBITNet cash exceeds market value 0.28xMedian 27.8x Not meaningful —
EV/RevenueNet cash exceeds market value −7.06xMedian 3.25x Not meaningful —
EV/FCFNet cash exceeds market value 0.44xMedian 26.6x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 0.44xMedian 21.9x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.86 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −51.3%Median 8.9% 4^th
Revenue CAGR (3Y) —Median 8.4% No data —
Gross profit growth (1Y) −41.1%Median 12.5% 5^th
Gross profit CAGR (3Y) —Median 8.7% No data —
Operating income growth (1Y) 64.8%Median 8.7% 85^th
Operating income CAGR (3Y) 0.6%Median 8.1% 37^th
Net income growth (1Y) 76.9%Median 8.7% 86^th
Net income CAGR (3Y) 15.3%Median 9.3% 60^th
EPS growth (1Y) 99.9%Median 27.5% 90^th
EPS CAGR (3Y) 55.8%Median 21.0% 86^th
Operating cash flow growth (1Y) −88.7%Median 5.7% 9^th
Operating cash flow CAGR (3Y) 1.6%Median 11.6% 34^th
Free cash flow growth (1Y) −88.5%Median 4.2% 11^th
Free cash flow CAGR (3Y) 15.2%Median 14.6% 51^st

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 80.4%Median 58.5% 92^nd
EBITDA margin −2,504%Median −4.7% 5^th
Operating margin −2,525%Median −10.0% 7^th
Pretax margin −1,579%Median −13.5% 8^th
Net margin −1,579%Median −14.9% 8^th
FCF margin −1,599%Median −2.7% 5^th
Operating cash flow margin −1,599%Median −0.5% 5^th
Return on equity −80.9%Median −24.8% 26^th
Return on assets −65.2%Median −17.3% 27^th
Return on invested capital —Median 1.3% No data —
Return on capital employed −129%Median −16.7% 15^th
Asset turnover 0.04xMedian 0.57x 7^th
Cash conversion (OCF / net income)Net income is not positive 1.01xMedian 1.51x Not meaningful —
Stock comp / revenue 6.8%Median 5.8% 46^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 0.9%Median 29.9% 93^rd
Debt / equity 0.01xMedian 0.46x 92^nd
Net debt / EBITDAEBITDA is not positive 0.36xMedian 2.17x Not meaningful —
Debt / FCFFree cash flow is not positive −0.01xMedian 4.10x Not meaningful —
Liabilities / assets 18.0%Median 45.3% 84^th
Equity / assets 82.0%Median 54.7% 84^th
Interest coverage −52.4xMedian −2.48x 11^th
Current ratio 2.21xMedian 2.98x 38^th
Quick ratio 2.02xMedian 1.83x 54^th
Cash ratio 2.02xMedian 1.15x 64^th
Altman Z-score −14.5Median 1.45 13^th

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 1.0% No dividend —
Net buyback yieldAbove 100% of market value −377%Median −0.2% Not meaningful —
Shareholder yieldAbove 100% of market value −377%Median −0.1% Not meaningful —
Payout ratio (earnings) —Median 29.0% No dividend —
Payout ratio (FCF) —Median 21.9% No dividend —
Dividend growth (1Y) —Median −0.9% No dividend —
Dividend CAGR (3Y) —Median −0.2% No dividend —

Peer group

Peer Comparison

Companies in the Diagnostic Equipment

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	254.87 Bn	36.58	5.50	42.55 Bn
2	ABT	Abbott Laboratories	178.85 Bn	32.97	3.84	32.61 Bn
3	DHR	Danaher Corp /De/	158.49 Bn	39.58	6.31	26.56 Bn
4	ISRG	Intuitive Surgical Inc	154.99 Bn	49.38	14.05	-
5	MDT	Medtronic plc	121.02 Bn	23.14	3.22	28.15 Bn
6	SYK	Stryker Corp	116.94 Bn	31.36	4.53	14.94 Bn
7	BSX	Boston Scientific Corp	66.98 Bn	18.23	3.19	12.62 Bn
8	ONCO	Onconetix, Inc.	0.00 Bn	-0.09	1.38	0.00 Bn